Format

Send to

Choose Destination
Clin Pharmacol Ther. 2015 Jul;98(1):47-60. doi: 10.1002/cpt.132. Epub 2015 May 19.

Optimizing Central Nervous System Drug Development Using Molecular Imaging.

Author information

1
Biogen, Cambridge, Massachusetts, USA.
2
inviCRO, LLC, Boston, Massachusetts, USA.
3
Merck Research Laboratories, West Point, Pennsylvania, USA.

Abstract

Advances in multimodality fusion imaging technologies promise to accelerate the understanding of the systems biology of disease and help in the development of new therapeutics. The use of molecular imaging biomarkers has been proven to shorten cycle times for central nervous system (CNS) drug development and thereby increase the efficiency and return on investment from research. Imaging biomarkers can be used to help select the molecules, doses, and patients most likely to test therapeutic hypotheses by stopping those that have little chance of success and accelerating those with potential to achieve beneficial clinical outcomes. CNS imaging biomarkers have the potential to drive new medical care practices for patients in the latent phases of progressive neurodegenerative disorders by enabling the detection, preventative treatment, and tracking of disease in a paradigm shift from today's approaches that have to see the overt symptoms of disease before treating it.

PMID:
25869938
DOI:
10.1002/cpt.132
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center